Utilization of palliative chemotherapy for advanced bladder cancer: Patterns of care in routine clinical practice.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 6525-6525
Author(s):  
Andrew George Robinson ◽  
Xuejiao Wei ◽  
William J. Mackillop ◽  
Christopher M. Booth
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Palliative Chemotherapy ◽  
Routine Clinical Practice ◽  
Patterns Of Care ◽  
Advanced Bladder Cancer

Use of Palliative Chemotherapy for Advanced Bladder Cancer: Patterns of Care in Routine Clinical Practice

2016 ◽  
Vol 14 (3) ◽  
pp. 291-298 ◽  
Author(s):  
Andrew G. Robinson ◽  
Xuejiao Wei ◽  
William J. Mackillop ◽  
Yingwei Peng ◽  
Christopher M. Booth
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Palliative Chemotherapy ◽  
Routine Clinical Practice ◽  
Patterns Of Care ◽  
Advanced Bladder Cancer

scholarly journals Assessment of Luminal and Basal Phenotypes in Bladder Cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Charles C. Guo ◽  
Jolanta Bondaruk ◽  
Hui Yao ◽  
Ziqiao Wang ◽  
Li Zhang ◽  
...  
Keyword(s):  
Primary Care ◽  
Bladder Cancer ◽  
Clinical Practice ◽  
Molecular Subtypes ◽  
Routine Clinical Practice ◽  
Cancer Center ◽  
Genomic Profiling ◽  
Protein Expressions ◽  
Cancer Tumor ◽  
Md Anderson

Abstract Genomic profiling studies have demonstrated that bladder cancer can be divided into two molecular subtypes referred to as luminal and basal with distinct clinical behaviors and sensitivities to frontline chemotherapy. We analyzed the mRNA expressions of signature luminal and basal genes in bladder cancer tumor samples from publicly available and MD Anderson Cancer Center cohorts. We developed a quantitative classifier referred to as basal to luminal transition (BLT) score which identified the molecular subtypes of bladder cancer with 80–94% sensitivity and 83–93% specificity. In order to facilitate molecular subtyping of bladder cancer in primary care centers, we analyzed the protein expressions of signature luminal (GATA3) and basal (KRT5/6) markers by immunohistochemistry, which identified molecular subtypes in over 80% of the cases. In conclusion, we provide a tool for assessment of molecular subtypes of bladder cancer in routine clinical practice.

7187 Clinical effectiveness of palliative chemotherapy for advanced bladder cancer

2009 ◽  
Vol 7 (2) ◽  
pp. 449
Author(s):  
J. Savva-Bordalo ◽  
M. Ferreira ◽  
A. Araújo ◽  
N. Sousa ◽  
J. Maurício ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Palliative Chemotherapy ◽  
Clinical Effectiveness ◽  
Advanced Bladder Cancer

Curative Therapy for Bladder Cancer in Routine Clinical Practice: A Population-based Outcomes Study

2014 ◽  
Vol 26 (8) ◽  
pp. 506-514 ◽  
Author(s):  
C.M. Booth ◽  
D.R. Siemens ◽  
G. Li ◽  
Y. Peng ◽  
W. Kong ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Population Based ◽  
Routine Clinical Practice ◽  
Curative Therapy ◽  
Outcomes Study

scholarly journals OC-0424: SBRT for Primary Liver Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome Analysis

2017 ◽  
Vol 123 ◽  
pp. S224
Author(s):  
T. Brunner ◽  
N. Andratschke ◽  
S. Gerum ◽  
N. Abbasi-Senger ◽  
M. Duma ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Routine Clinical Practice ◽  
Patterns Of Care ◽  
Outcome Analysis

scholarly journals Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice

2014 ◽  
Vol 25 (9) ◽  
pp. 1783-1788 ◽  
Author(s):  
C.M. Booth ◽  
D.R. Siemens ◽  
Y. Peng ◽  
I.F. Tannock ◽  
W.J. Mackillop
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Routine Clinical Practice ◽  
Perioperative Chemotherapy

Diagnosis and Management of Cardiomyopathies – A Focus on Genetics, Cardiac Magnetic Resonance and Clinical Features

2011 ◽  
Vol 7 (3) ◽  
pp. 225
Author(s):  
Gianfranco Sinagra ◽  
Michele Moretti ◽  
Giancarlo Vitrella ◽  
Marco Merlo ◽  
Rossana Bussani ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Cardiac Magnetic Resonance ◽  
Magnetic Resonance ◽  
Imaging Techniques ◽  
Molecular Genetic ◽  
Molecular Genetic Analysis ◽  
Routine Clinical Practice ◽  
Clinical Approach ◽  
Diagnosis And Management ◽  
Made In

In recent years, outstanding progress has been made in the diagnosis and treatment of cardiomyopathies. Genetics is emerging as a primary point in the diagnosis and management of these diseases. However, molecular genetic analyses are not yet included in routine clinical practice, mainly because of their elevated costs and execution time. A patient-based and patient-oriented clinical approach, coupled with new imaging techniques such as cardiac magnetic resonance, can be of great help in selecting patients for molecular genetic analysis and is crucial for a better characterisation of these diseases. This article will specifically address clinical, magnetic resonance and genetic aspects of the diagnosis and management of cardiomyopathies.

Sign in / Sign up

Export Citation Format

Share Document